

Supplementary Table. Clinical variables of the 136 chronic kidney disease patients divided by low and high L-carnitine value

Characteristics	All Participants (N = 136)	Low LC (N = 103)	High LC (N = 33)	<i>p</i> -Value
Age (years)	67.75 ± 12.73	68.72 ± 12.92	64.73 ± 11.79	0.117
Height (cm)	158.24 ± 9.69	156.89 ± 9.74	162.42 ± 8.37	0.004*
Body weight (kg)	65.38 ± 14.80	64.74 ± 15.28	67.37 ± 13.21	0.378
BMI (kg/m ²)	25.94 ± 4.41	26.09 ± 4.45	25.46 ± 4.34	0.473
cfPWV (m/s)	8.85 (7.40-10.80)	9.3 (7.80-11.575)	7.5 (6.65-8.425)	0.0002*
SBP (mmHg)	149.80 ± 26.47	153.92 ± 27.71	136.94 ± 19.89	0.001*
DBP (mmHg)	84.57 ± 13.92	85.96 ± 14.24	80.21 ± 12.05	0.039*
TCH (mg/dL)	159.31 ± 43.66	158.97 ± 40.98	160.36 ± 51.82	0.874
Triglyceride (mg/dL)	119.0 (86.00-161.25)	119.0 (86.0-165.0)	116.0 (92.75-146.25)	0.751
LDL-C (mg/dL)	89.29 ± 36.77	86.56 ± 33.91	97.82 ± 44.04	0.126
Fasting glucose (mg/dL)	99.00 (92.00-138.75)	99.00 (92.0-141.25)	97.00 (93.0-122.75)	0.384
HbA1c, (%)	6.2 (5.975-7.5)	6.20 (5.9-7.6)	6.3 (6.0-6.975)	0.898
BUN (mg/dL)	33.00 (24.00-44.00)	32.00 (24.0-44.0)	38.0 (23.75-60.75)	0.337
Creatinine (mg/dL)	1.85 (1.43-2.60)	1.80 (1.425-2.5)	2.2 (1.475-3.075)	0.446
Albumin (mg/dL)	4.00 (3.90-4.30)	4.00 (3.90-4.30)	4.00 (3.90-4.225)	0.754
eGFR (mL/min)	31.39 ± 15.15	31.11 ± 14.86	32.28 ± 16.22	0.700
Total Ca (mg/dL)	9.17 ± 1.88	9.23 ± 1.85	8.99 ± 2.01	0.532
Phosphorus (mg/dL)	3.85 ± 0.81	3.87 ± 0.81	3.77 ± 0.84	0.535
L-carnitine (μmol/L)	33.45 (25.22-39.87)	27.77 (23.91-35.33)	48.23 (42.37-59.72)	< 0.0001*
Female, <i>n</i> (%)	67 (49.3)	58 (56.3)	9 (27.3)	0.007*
DM, <i>n</i> (%)	51 (37.5)	39 (37.9)	12 (36.4)	0.959
HTN, <i>n</i> (%)	108 (79.4)	81 (78.6)	27 (81.8)	0.884
GN, <i>n</i> (%)	38 (27.9)	31 (30.1)	7 (21.2)	0.443
Smoking, <i>n</i> (%)	12 (9.0)	9 (8.7)	3 (9.1)	0.749
ARB use, <i>n</i> (%)	59 (43.4)	41 (39.8)	18 (54.5)	0.199
β-blocker use, <i>n</i> (%)	33 (24.3)	25 (24.3)	8 (24.2)	0.818
α-blocker use, <i>n</i> (%)	18 (13.2)	11 (10.7)	7 (21.2)	0.208
CCB use, <i>n</i> (%)	54 (39.7)	43 (41.7)	11 (33.3)	0.512
Statin use, <i>n</i> (%)	67 (49.3)	54 (52.4)	13 (39.4)	0.270
Fibrate use, <i>n</i> (%)	10 (7.4)	5 (4.9)	5 (15.2)	0.112
CKD stage 3, <i>n</i> (%)	68 (50.0)	51 (49.5)	17 (51.5)	0.914
CKD stage 4, <i>n</i> (%)	41 (30.1)	32 (31.1)	9 (27.3)	
CKD stage 5, <i>n</i> (%)	27 (19.9)	20 (19.4)	7 (21.2)	

Values for continuous variables are given as mean ± standard deviation and tested by Student's *t*-test; variables not normally distributed are given as median and interquartile range and tested by Mann-Whitney U test; values are presented as number (%) and analysis was done using the chi-square test.

cfPWV, carotid-femoral pulse wave velocity; DM, diabetes mellitus; HTN, hypertension; BMI, body mass index; TCH, total cholesterol; Ca, calcium; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. **p* < 0.05 was considered statistically significant.